CTI tries for incremental FDA approval
Computerized Thermal Imaging has submitted three of five data packages, or what the company is calling "modules," to the FDA as part of its premarket approval application for a breast cancer detection system that uses a heat sensitive camera. The
Computerized Thermal Imaging has submitted three of five data packages, or what the company is calling "modules," to the FDA as part of its premarket approval application for a breast cancer detection system that uses a heat sensitive camera.
The modules are data packages explaining to the FDA how the company's Computer Thermal Imaging system works. The system consists of a patient table and heat-sensitive camera and uses the company's proprietary computer algorithms.
The CTI camera can be used in conjunction with an x-ray mammography system, said Dee Rose, CTI spokesperson.
CTI was founded in 1987 by business partners who recognized that thermal imaging coupled with sophisticated software could differentiate healthy from suspicious tissue because of heat generated by the increased vascularity associated with tumors.
The firm believes that data generated by the CTI system can assist physicians in detecting the presence of numerous diseases, disorders, and injuries within the body's physiological, neurological, and vascular systems that conventional imaging systems such as x-ray, CT, or MR may miss.
The modules are being considered by the FDA in separate pieces. The first module was approved by the FDA at the end of last year. The second was submitted in February and is still under review.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
